Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GB 3010

Next Previous
Drug Profile

GB 3010

Alternative Names: GB-3010

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Genechem
  • Developer Shanghai Genbase Biotechnology; Shanghai Genechem
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Pancreatic cancer

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-0 development in Pancreatic-cancer(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (IV, Injection)
  • 25 Apr 2022 GB 3010 is available for licensing as of 25 Apr 2022. https://www.gcbio.com/
  • 07 Sep 2021 Preclinical trials in Pancreatic cancer in China (IV, Injection) before September 2021 (NCT06054984)(Shanghai Genechem pipeline, April 2022) (Shanghai Genbase Biotechnology pipeline, April 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top